ストックスクリーナーアプリを入手
4.14
37.50%
1.12
前日終値:
$3.02
開ける：
$4.29
24時間の取引高:
43.15M
Relative Volume:
468.03
時価総額：
$26.53M
収益：
-
当期純損益:
$-11.46M
株価収益率:
-0.2957
EPS:
-14
ネットキャッシュフロー:
$-24.56M
1週間 パフォーマンス:
+12.82%
1か月 パフォーマンス:
+1.54%
6か月 パフォーマンス:
+78.38%
1年 パフォーマンス:
-77.78%
1日の値動き範囲:
$4.16
$4.31
1週間の範囲:
$2.85
$3.34
52週間の値動き範囲:
$1.20
$16.10
Evaxion A S Adr Stock (EVAX) Company Profile
EVAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
4.1995 | 19.08M | 0 | -11.46M | -24.56M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
384.75 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.84 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
455.00 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
723.03 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
330.14 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Evaxion A S Adr Stock (EVAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-02 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2024-02-12 | 開始されました | H.C. Wainwright | Buy |
Evaxion A S Adr (EVAX) 最新ニュース
Evaxion A/S (NASDAQ:EVAX) Trading Down 0.7% – Should You Sell? - Defense World
Evaxion Biotech A/S Adr Earnings Call: Strategic Growth Amid Challenges - TipRanks
Evaxion Biotech Reports Q2 2025 Financial Results - MSN
Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gains 2% for Week - MSN
XTX Topco Ltd Makes New Investment in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) - Defense World
Short Interest in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Expands By 148.8% - Defense World
Evaxion Boosts Equity through Debt Conversion, Improves Financial Flexibility - AInvest
Healthcare Stocks to Watch: Evaxion Biotech, CVRx, and Rockwell Medical Receive Bullish Sentiments - AInvest
Biotech Contrarians: Seizing Value in Europe's ADRs Amid Sectoral Slump - AInvest
European ADRs Dip As Evaxion And Grifols Climb - Finimize
European ADRs Dip While Biotech And Energy See Gains - Finimize
EVAX: Grant For Polio Vaccine Announced - Research Tree
Evaxion Biotech’s Earnings Call Highlights Progress and Challenges - MSN
Evaxion Biotech Reports Q1 2025 Progress and Financials - TipRanks
European ADRs Rise On S&P Europe Select Index - Finimize
European Equities See Growth In US Trade - Finimize
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - GlobeNewswire Inc.
Evaxion’s EVX-01 vaccine shows promising immune response in trial - Investing.com
European Equities Traded in the US as American Depositary Receipts Sharply Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
European Stocks Slip In US Trading With Mixed Performances - Finimize
Evaxion Biotech’s Optimistic Earnings Call Highlights - TipRanks
Evaxion Biotech Reports 2024 Financial Results and Strategic Progress - TipRanks
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
Evaxion Biotech stock plunges to 52-week low of $1.7 amid steep annual decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - TradingView
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $1.79 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
EVAX: Extended Trial is Excellent News - Research Tree
Evaxion Biotech stock hits 52-week low at $2.22 amid sharp decline - Investing.com
Evaxion secures Nasdaq listing with equity boost - Investing.com
H.C. Wainwright maintains Evaxion stock Buy rating, $14 target - Investing.com
Evaxion Biotech stock hits 52-week low at $2.38 amid market challenges - Investing.com
Evaxion Biotech stock hits 52-week low at $3.06 amid sharp decline - Investing.com
Evaxion Biotech Completes 1:5 Reverse ADS Split: What Investors Need to Know - Stock Titan
Evaxion Biotech stock hits 52-week low at $0.81 amid market challenges - Investing.com
Evaxion Biotech A/S Announces Change in American Depositary Shares Ratio to Enhance Liquidity - Nasdaq
Evaxion Biotech stock hits 52-week low at $0.84 amid market challenges - Investing.com
Evaxion Biotech stock hits 52-week low at $0.92 - Investing.com
Earnings call: Evaxion Biotech reports Q2 results, optimistic on EVX-01 - Investing.com
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data - Yahoo Finance
European Equities Traded as American Depositary Receipts Down Fall - TradingView
Bears are Losing Control Over Evaxion Biotech AS Sponsored ADR (EVAX), Here's Why It's a 'Buy' Now - Nasdaq
Evaxion Biotech (EVAX) Stock Price Fell 44% Premarket After Discounted Share Issue - AskTraders.com
Evaxion Biotech (EVAX) Stock Price Soared 236.9% Premarket Amid Buying Pressure - AskTraders.com
EVAX Stock Price and Chart — NASDAQ:EVAX - TradingView
EVAX News Today | Why did Evaxion Biotech A/S stock go down today? - MarketBeat
Evaxion A S Adr (EVAX) 財務データ
収益
当期純利益
現金流量
EPS
1.30%
2.51%
大文字化:
|
ボリューム (24 時間):